<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Currently, relatively safe, reliable resection techniques are available for most patients with <z:hpo ids='HP_0011459'>esophageal carcinoma</z:hpo> who present with nonmetastatic disease </plain></SENT>
<SENT sid="1" pm="."><plain>For optimal results, the surgeon must be familiar with both transhiatal and transthoracic approaches and must individualize the approach depending on the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size and location and the patient's functional status </plain></SENT>
<SENT sid="2" pm="."><plain>Whereas post-resection survival rates are good for patients with early-stage disease (Stage I or IIa), most patients present with locally advanced, Stage III disease </plain></SENT>
<SENT sid="3" pm="."><plain>Although some progress has been made in the past decade in regard to early diagnosis among patients with Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> undergoing endoscopic surveillance and additional progress has been made in adapting multimodality treatment programs successfully to patients with locally advanced disease, the overall cure rate for patients with <z:hpo ids='HP_0011459'>esophageal carcinoma</z:hpo> remains low </plain></SENT>
</text></document>